- Home
- SG vs CNTA Comparison
SG vs CNTA Comparison
Compare SG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SG
- CNTA
- Stock Information
- Founded
- SG 2007
- CNTA 2020
- Country
- SG United States
- CNTA United Kingdom
- Employees
- SG N/A
- CNTA N/A
- Industry
- SG Restaurants
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- SG Consumer Discretionary
- CNTA Health Care
- Exchange
- SG Nasdaq
- CNTA Nasdaq
- Market Cap
- SG 1.8B
- CNTA 1.6B
- IPO Year
- SG 2021
- CNTA 2021
- Fundamental
- Price
- SG $13.30
- CNTA $14.30
- Analyst Decision
- SG Buy
- CNTA Strong Buy
- Analyst Count
- SG 14
- CNTA 10
- Target Price
- SG $24.69
- CNTA $28.78
- AVG Volume (30 Days)
- SG 5.2M
- CNTA 999.0K
- Earning Date
- SG 08-07-2025
- CNTA 08-12-2025
- Dividend Yield
- SG N/A
- CNTA N/A
- EPS Growth
- SG N/A
- CNTA N/A
- EPS
- SG N/A
- CNTA N/A
- Revenue
- SG $685,280,000.00
- CNTA $15,000,000.00
- Revenue This Year
- SG $13.88
- CNTA N/A
- Revenue Next Year
- SG $19.96
- CNTA N/A
- P/E Ratio
- SG N/A
- CNTA N/A
- Revenue Growth
- SG 11.10
- CNTA 118.88
- 52 Week Low
- SG $11.86
- CNTA $9.00
- 52 Week High
- SG $45.12
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- SG 45.89
- CNTA 59.61
- Support Level
- SG $12.94
- CNTA $13.22
- Resistance Level
- SG $15.07
- CNTA $14.14
- Average True Range (ATR)
- SG 0.87
- CNTA 0.68
- MACD
- SG 0.16
- CNTA 0.10
- Stochastic Oscillator
- SG 45.52
- CNTA 86.77
About SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.